Neuroimaging Enrichment Strategy for Secondary Prevention Trials in Alzheimer Disease

We examined the improvement in statistical power that could be obtained in therapeutic trials for early (predementia) Alzheimer disease by constraining enrollment to individuals with amnestic mild cognitive impairment (MCI) and an atrophy pattern on a screening magnetic resonance imaging (MRI) scan previously found to be predictive of clinical decline, or to individuals with MCI and the apolipoprotein E ϵ4 genetic risk factor for Alzheimer disease. Treatable effects were defined as absolute change versus change relative to healthy controls (HCs). Data from 168 HC and 299 MCI participants were analyzed to determine sample sizes required to detect 25% slowing in mean rate of decline using global function, cognitive function, and structural measures as outcome variables. Reductions in estimated sample sizes of 10% to 43% were observed using the genetic enrichment strategy; reductions of 43% to 60% were observed with the neuroimaging enrichment strategy. Sample sizes needed to detect slowing in rate of atrophy in MCI relative to HC were dramatically larger than those needed to detect absolute change in atrophy rates. Constraining enrollment to MCI subjects with predictive atrophy on a screening MRI scan could improve the efficiency of clinical trials. Failure to take into account normal age-related changes risks under-powering trials designed to test disease-modifying properties of potential treatments.

[1]  Bruno Vellas,et al.  Disease-modifying trials in Alzheimer's disease: a European task force consensus , 2007, The Lancet Neurology.

[2]  J. Price,et al.  Mild cognitive impairment represents early-stage Alzheimer disease. , 2001, Archives of neurology.

[3]  et al.,et al.  Spatial patterns of brain atrophy in MCI patients, identified via high-dimensional pattern classification, predict subsequent cognitive decline , 2008, NeuroImage.

[4]  P. Amouyel,et al.  Genetic susceptibility factors for Alzheimer's disease. , 2001, European journal of pharmacology.

[5]  C. Jack,et al.  Rates of hippocampal atrophy correlate with change in clinical status in aging and AD , 2000, Neurology.

[6]  B. Winblad,et al.  Clinical trials in mild cognitive impairment: lessons for the future , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[7]  C. P. Hughes,et al.  A New Clinical Scale for the Staging of Dementia , 1982, British Journal of Psychiatry.

[8]  C. Jack,et al.  MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment , 2008, Neurology.

[9]  C. Jack,et al.  MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers , 2008, Brain : a journal of neurology.

[10]  A M Dale,et al.  Measuring the thickness of the human cerebral cortex from magnetic resonance images. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[11]  A. Dale,et al.  Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. , 2009, Radiology.

[12]  Anders M. Dale,et al.  An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest , 2006, NeuroImage.

[13]  S. Resnick,et al.  Longitudinal Magnetic Resonance Imaging Studies of Older Adults: A Shrinking Brain , 2003, The Journal of Neuroscience.

[14]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[15]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[16]  Hiroko H Dodge,et al.  Functional transitions and active life expectancy associated with Alzheimer disease. , 2003, Archives of neurology.

[17]  Keith A. Johnson,et al.  Neuropathology of Cognitively Normal Elderly , 2003, Journal of neuropathology and experimental neurology.

[18]  Anders M. Dale,et al.  Sequence-independent segmentation of magnetic resonance images , 2004, NeuroImage.

[19]  André J W van der Kouwe,et al.  Real‐time rigid body motion correction and shimming using cloverleaf navigators , 2006, Magnetic resonance in medicine.

[20]  N. Schuff,et al.  Higher atrophy rate of entorhinal cortex than hippocampus in AD , 2004, Neurology.

[21]  A. Dale,et al.  Structural MRI biomarkers for preclinical and mild Alzheimer's disease , 2009, Human brain mapping.

[22]  Dan Rettmann,et al.  PROMO: Real‐time prospective motion correction in MRI using image‐based tracking , 2010, Magnetic resonance in medicine.

[23]  C. Jack,et al.  Alzheimer's Disease Neuroimaging Initiative , 2008 .

[24]  A. Dale,et al.  Cortical Surface-Based Analysis II: Inflation, Flattening, and a Surface-Based Coordinate System , 1999, NeuroImage.

[25]  D. Bennett,et al.  Mild cognitive impairment: is it Alzheimer's disease or not? , 2005, Journal of Alzheimer's disease : JAD.

[26]  Alan C. Evans,et al.  A nonparametric method for automatic correction of intensity nonuniformity in MRI data , 1998, IEEE Transactions on Medical Imaging.

[27]  P1-249: Longitudinal nonlinear registration and quantitative analysis of change in whole brain and regions of interest , 2008, Alzheimer's & Dementia.

[28]  D. A. Bennett,et al.  Rate of entorhinal and hippocampal atrophy in incipient and mild AD: Relation to memory function , 2010, Neurobiology of Aging.

[29]  Anders M. Dale,et al.  Cortical Surface-Based Analysis I. Segmentation and Surface Reconstruction , 1999, NeuroImage.

[30]  Anders M. Dale,et al.  Reliability in multi-site structural MRI studies: Effects of gradient non-linearity correction on phantom and human data , 2006, NeuroImage.

[31]  A. Dale,et al.  Improved Localizadon of Cortical Activity by Combining EEG and MEG with MRI Cortical Surface Reconstruction: A Linear Approach , 1993, Journal of Cognitive Neuroscience.

[32]  Safety and efficacy of galantamine in subjects with mild cognitive impairment , 2010, Neurology.

[33]  A. Burns.  Clinical diagnosis of Alzheimer's disease , 1991 .

[34]  D. Bennett,et al.  Vitamin E and donepezil for the treatment of mild cognitive impairment. , 2005, The New England journal of medicine.

[35]  Cheryl L. Dahle,et al.  Regional brain changes in aging healthy adults: general trends, individual differences and modifiers. , 2005, Cerebral cortex.

[36]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[37]  R. Petersen.  Mild cognitive impairment as a diagnostic entity , 2004, Journal of internal medicine.

[38]  C. Jack,et al.  Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI , 2005, Neurology.

[39]  Charles D. Smith,et al.  Neuropathologic substrate of mild cognitive impairment. , 2006, Archives of neurology.

[40]  C. Jack,et al.  MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD , 2003, Neurology.

[41]  Nikos Makris,et al.  Automatically parcellating the human cerebral cortex. , 2004, Cerebral cortex.

[42]  Nick C Fox,et al.  Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. , 2000, Archives of neurology.

[43]  J. Ware,et al.  Applied Longitudinal Analysis , 2004 .

[44]  B. L. Miller,et al.  Atrophy rates of entorhinal cortex in AD and normal aging , 2003, Neurology.

[45]  Nick C Fox,et al.  A longitudinal study of brain volume changes in normal aging using serial registered magnetic resonance imaging. , 2003, Archives of neurology.

[46]  M N Rossor,et al.  Measuring atrophy in Alzheimer disease , 2005, Neurology.

[47]  Nick C Fox,et al.  The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.

[48]  C. Jack,et al.  Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD , 2004, Neurology.

[49]  D. Pleasure.  Genetics of Charcot-Marie-Tooth disease. , 2003, Archives of neurology.

[50]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[51]  R. Mayeux,et al.  Hippocampal and entorhinal atrophy in mild cognitive impairment , 2007, Neurology.

[52]  A. Dale,et al.  Regional rates of neocortical atrophy from normal aging to early Alzheimer disease , 2009, Neurology.

[53]  Norbert Schuff,et al.  Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: An ADNI study of 515 subjects , 2009, NeuroImage.